These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37053280)

  • 1. Cardiac Metabolism in Heart Failure and Implications for Uremic Cardiomyopathy.
    Nguyen TD; Schulze PC
    Circ Res; 2023 Apr; 132(8):1034-1049. PubMed ID: 37053280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance.
    Edwards NC; Moody WE; Chue CD; Ferro CJ; Townend JN; Steeds RP
    JACC Cardiovasc Imaging; 2014 Jul; 7(7):703-14. PubMed ID: 25034920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
    Grabner A; Faul C
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-oxidative priming but maintained cardiac function in a broad spectrum of murine models of chronic kidney disease.
    Wollenhaupt J; Frisch J; Harlacher E; Wong DWL; Jin H; Schulte C; Vondenhoff S; Moellmann J; Klinkhammer BM; Zhang L; Baleanu-Curaj A; Liehn EA; Speer T; Kazakov A; Werner C; van der Vorst EPC; Selejan SR; Hohl M; Böhm M; Kramann R; Biessen EAL; Lehrke M; Marx N; Jankowski J; Maack C; Boor P; Prates Roma L; Noels H
    Redox Biol; 2022 Oct; 56():102459. PubMed ID: 36099852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
    Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
    J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
    Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW
    Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
    Xie J; Wu YL; Huang CL
    Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
    Xie J; Yoon J; An SW; Kuro-o M; Huang CL
    J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is uremic cardiomyopathy a direct consequence of chronic kidney disease?
    Chinnappa S; Hothi SS; Tan LB
    Expert Rev Cardiovasc Ther; 2014 Feb; 12(2):127-30. PubMed ID: 24404903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.
    Law JP; Pickup L; Pavlovic D; Townend JN; Ferro CJ
    J Hum Hypertens; 2023 Jan; 37(1):1-19. PubMed ID: 36138105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremic cardiomyopathy and insulin resistance: a critical role for akt?
    Semple D; Smith K; Bhandari S; Seymour AM
    J Am Soc Nephrol; 2011 Feb; 22(2):207-15. PubMed ID: 20634295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac metabolic remodelling in chronic kidney disease.
    Patel N; Yaqoob MM; Aksentijevic D
    Nat Rev Nephrol; 2022 Aug; 18(8):524-537. PubMed ID: 35637381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early inflammatory changes and CC chemokine ligand-8 upregulation in the heart contribute to uremic cardiomyopathy.
    Amador-Martínez I; García-Ballhaus J; Buelna-Chontal M; Cortés-González C; Massó F; Jaisser F; Barrera-Chimal J
    FASEB J; 2021 Aug; 35(8):e21761. PubMed ID: 34245616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy.
    Wang X; Liu J; Drummond CA; Shapiro JI
    Expert Opin Ther Targets; 2017 May; 21(5):531-541. PubMed ID: 28338377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of murine models of uremic cardiomyopathy.
    Soppert J; Frisch J; Wirth J; Hemmers C; Boor P; Kramann R; Vondenhoff S; Moellmann J; Lehrke M; Hohl M; van der Vorst EPC; Werner C; Speer T; Maack C; Marx N; Jankowski J; Roma LP; Noels H
    Kidney Int; 2022 Feb; 101(2):256-273. PubMed ID: 34774555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
    Alex L; Russo I; Holoborodko V; Frangogiannis NG
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
    Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
    J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac magnetic resonance and uremic cardiomyopathy].
    Di Lullo L; Gorini A; Rivera R; De Pascalis A; Bellasi A; Russo D; Barbera V; Ronco C; Balducci A; Santoboni A
    G Ital Nefrol; 2014; 31(6):. PubMed ID: 25504164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Remodeling in Chronic Kidney Disease.
    Kaesler N; Babler A; Floege J; Kramann R
    Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32150864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy.
    Kovács ZZA; Szűcs G; Freiwan M; Kovács MG; Márványkövi FM; Dinh H; Siska A; Farkas K; Kovács F; Kriston A; Horváth P; Kővári B; Cserni BG; Cserni G; Földesi I; Csont T; Sárközy M
    Sci Rep; 2021 Sep; 11(1):17495. PubMed ID: 34471171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.